

EPIX Pharmaceuticals, Inc.  
Form 8-K/A  
April 29, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**Amendment No. 1 to**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **April 28, 2005**

## **EPIX Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K/A

(State or Other Jurisdiction of Incorporation)

**000-21863**

(Commission File Number)

**04-3030815**

(IRS Employer Identification No.)

**161 First Street, Cambridge, Massachusetts**

**02142**

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K/A

(Address of Principal Executive Offices)

(Zip Code)

**(617) 250-6000**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

This Amendment No. 1 to Form 8-K is being filed solely to correct a typographical error in the press release that is furnished as Exhibit 99.1 hereto, in the condensed balance sheet information for the period ended December 31, 2004.

**Item 2.02. Results of Operations and Financial Condition.**

On April 28, 2005, EPIX Pharmaceuticals, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2005. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

The information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

<b>Exhibit Number</b>	<b>Description</b>
99.1	Corrected Press Release dated April 28, 2005.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment No. 1 to Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

**EPIX Pharmaceuticals, Inc.**

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K/A

(Registrant)

Date: April 29, 2005

/s/ Peyton J. Marshall

Peyton J. Marshall  
*Senior Vice-President,  
Finance and Administration,  
Chief Financial Officer*

3

---